Regulatory approval of OVM-200 for Phase 1 signals a significant step for Oxford Vacmedix with the first clinical trial of a cancer vaccine based on the recombinant overlapping peptide platform Oxford 10th August 2021; Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that approval for a Phase 1 …
MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200 Read More »
Oxford Vacmedix UK Ltd announces the appointment of Mark Thomas as Head of Clinical Operations, bringing in-depth expertise in running clinical trials and in pharmaceutical development to Oxford Vacmedix. Press Release – appointment of Mark Thomas as Head of Clinical Operations Oxford, 14th June 2021: Oxford Vacmedix, the UK-based biopharma company focused on the development …
Mark Thomas appointed as Head of Clinical Operations Read More »
Oxford Vacmedix UK Ltd announces the appointment of Dr Thomas Morris as Chief Medical Officer, bringing in-depth expertise in oncology clinical development to the Company. Press Release – Dr Thomas Morris appointed as Chief Medical Officer Oxford, 23rd March 2021: Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today …
Dr Thomas Morris appointed as Chief Medical Officer Read More »
Oxford Vacmedix and CHAIN Biotech have signed Heads of Terms for a Collaboration Agreement to develop and commercialise oral vaccines targeting cancer & infectious disease Oxford, UK – 4th January 2020 – FOR IMMEDIATE RELEASE Press Release – OVM CHAIN Collaboration Oxford 4th Jan 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on …
Oxford Vacmedix and CHAIN Biotech collaborate to develop oral vaccines Read More »
New patent using Recombinant Overlapping Peptide (ROP technology) as novel approach to SARS-Cov-2 pandemic filed, after rapid development and initial testing Oxford, UK – 24th November 2020 – FOR IMMEDIATE RELEASE Press Release-Patent filed for Covid-19 vaccine and diagnostics 24-11-20 Oxford 24th November 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on the …
Oxford Vacmedix announces filing of new patent for Covid-19 vaccine and diagnostics Read More »
Shisong Jiang is appointed to the newly created role of Senior Industrial Fellow in the Department of Oncology at the University of Oxford Oxford, UK – 9th November 2020 – FOR IMMEDIATE RELEASE Download PDF – Press Release-Senior Industrial Fellow 09-11-20 Oxford 9th November 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on …
Collaboration with the Nuffield Department of Medicine, University of Oxford will use recombinant overlapping peptide technology to develop a novel vaccine and diagnostic tests for Covid-19 Press Release Covid-19 project 12 May 2020 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focusing on the development of cancer vaccines, announced today that it will use …
Oxford Vacmedix appoints a Global Contract Research Organisation (CRO) to run a Phase 1 trial of immunotherapy cancer vaccine OVM-200 in the UK. Oxford, UK – 24th January 2020 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that a leading global CRO has been appointed …
Grant will fund joint research by Imperial College, London and Oxford Vacmedix into antimicrobial resistance, in collaboration with the Ditan Hospital in Beijing, China Oxford, UK – 19th December 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focusing on the development of cancer vaccines, announced today the award of an Innovate UK grant …
Oxford Vacmedix appoints Belgium based Eurofins CDMO to carry out the GMP manufacturing of the lead immunotherapy cancer vaccine OVM-200, to support Phase 1 application. Oxford, UK – 22nd November 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that Eurofins CDMO based in Belgium …